High Court Sends Myriad Gene Patent Row Back To Fed. Circ.

Law360, New York (March 26, 2012, 2:00 PM EDT) -- The U.S. Supreme Court on Monday ordered the Federal Circuit to take another look at its finding that breast cancer genes isolated by Myriad Genetics Inc. are patentable, in light of the high court's Mayo v. Prometheus decision that methods covering laws of nature alone are unpatentable.

The high court vacated and remanded the Federal Circuit's 2-1 ruling from July that the BRCA1 and BRCA2 genes isolated by Myriad fall within the realm of human-made inventions because they are "markedly different" from molecules that exist in nature.

On March 20, the Supreme Court unanimously held that Prometheus Laboratories Inc.'s blood testing...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!